<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03631732</url>
  </required_header>
  <id_info>
    <org_study_id>GS-US-380-4580</org_study_id>
    <nct_id>NCT03631732</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants</brief_title>
  <acronym>BRAAVE 2020</acronym>
  <official_title>A Phase 3b, Multicenter, Open-Label Study to Evaluate Switching From a Regimen of Two Nucleos(t)Ide Reverse Transcriptase Inhibitors (NRTI) Plus a Third Agent to a Fixed Dose Combination (FDC) of Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF), in Virologically-Suppressed, HIV-1 Infected African American Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gilead Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Gilead Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to evaluate the efficacy of switching from a regimen&#xD;
      of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent to a fixed dose&#xD;
      combination (FDC) of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) versus&#xD;
      continuing their baseline regimen in HIV-1 infected, virologically suppressed African&#xD;
      American participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 28, 2018</start_date>
  <completion_date type="Actual">August 19, 2020</completion_date>
  <primary_completion_date type="Actual">August 12, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set</measure>
    <time_frame>Week 24</time_frame>
    <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</measure>
    <time_frame>Week 48</time_frame>
    <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set</measure>
    <time_frame>Baseline to Week 48</time_frame>
    <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</measure>
    <time_frame>First B/F/TAF dose date up to Week 72 plus 30 days</time_frame>
    <description>An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities</measure>
    <time_frame>First B/F/TAF dose date up to Week 72 plus 30 days</time_frame>
    <description>Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">496</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will stay on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wish to continue on B/F/TAF will be given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they have access to B/F/TAF, whichever occurs first.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>B/F/TAF</intervention_name>
    <description>50/200/25 mg FDC tablets administered orally once daily without regard to food</description>
    <arm_group_label>B/F/TAF</arm_group_label>
    <arm_group_label>Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF</arm_group_label>
    <other_name>Biktarvy®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NRTIs</intervention_name>
    <description>The following NRTIs will be administered as prescribed until Week 24 without regard to food:&#xD;
abacavir (ABC), emtricitabine (FTC), lamivudine (3TC), tenofovir alafenamide (TAF), tenofovir disoproxil fumarate (TDF), zidovudine (ZDV or AZT)</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Third Agent</intervention_name>
    <description>Any one of the following third agents will be administered as prescribed. Protease inhibitors and EVG will be administered with the appropriate pharmacologic booster cobicistat or ritonavir. :&#xD;
Non-nucleoside reverse transcriptase inhibitors (NNRTIs)&#xD;
delavirdine (DLV)&#xD;
efavirenz (EFV)&#xD;
nevirapine (NVP)&#xD;
rilpivirine (RPV)&#xD;
doravirine (DOR)&#xD;
Integrase inhibitors&#xD;
dolutegravir (DTG)&#xD;
elvitegravir (EVG)&#xD;
raltegravir (RAL)&#xD;
Protease inhibitors (PIs)&#xD;
atazanavir (ATV)&#xD;
darunavir (DRV)&#xD;
lopinavir (LPV)&#xD;
nelfinavir NFV)&#xD;
saquinavir (SQV)&#xD;
tipranavir (TPV)&#xD;
Chemokine co-recptor 5 (CCR5) antagonist --maraviroc (MVC)</description>
    <arm_group_label>Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          -  Self-describes as Black, African American, or mixed race, including Black&#xD;
&#xD;
          -  Currently receiving an antiretrovirals (ARV) regimen other than FDC of B/F/TAF that&#xD;
             consists of any two NRTIs + allowed 3rd agent for ≥ 6 months&#xD;
&#xD;
          -  Allowed 3rd agents include any FDA-approved INSTI, with the exception of bictegravir,&#xD;
             any FDA-approved NNRTI with the exception of etravirine, protease inhibitors or the&#xD;
             CCR5 antagonist, maraviroc&#xD;
&#xD;
          -  If the baseline 3rd agent is dolutegravir, dosing other than 50 mg once daily is&#xD;
             excluded&#xD;
&#xD;
          -  Baseline regimens containing investigational drugs or &gt; 2 classes of ARVs are not&#xD;
             permitted, with the exception of the pharmacologic enhancers cobicistat (taken with&#xD;
             elvitegravir or a PI), or ritonavir (taken with a PI)&#xD;
&#xD;
          -  Have no documented or suspected resistance to INSTIs and no history of virologic&#xD;
             failure on an INSTI containing regimen (2 consecutive HIV-1 RNA ≥ 50 copies/mL after&#xD;
             achieving &lt;50 copies/mL while on an INSTI-containing regimen)&#xD;
&#xD;
          -  History of 1-2 thymidine analogue mutations (TAMs), M184V/I, and any other RT&#xD;
             substitutions are allowed, with the following exceptions: History of 3 or more TAMs&#xD;
             (M41L, D67N, K70R, L210W, T215F/Y, and K219Q/E/N/R), T69-insertions, or K65R/E/N in RT&#xD;
             will be excluded&#xD;
&#xD;
          -  Documented plasma HIV-1 RNA &lt; 50 copies/mL during treatment with the baseline regimen&#xD;
             for a minimum period of 6 months and at least the last two HIV-1 RNA measurements&#xD;
             prior to the Screening visit&#xD;
&#xD;
          -  HIV-1 RNA levels &lt; 50 copies/mL at Screening&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) ≥ 50 mL/min according to the&#xD;
             Cockcroft-Gault formula for creatinine clearance&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          -  History of 3 or more TAMs (M41L, D67N, K70R, L210W, T215F/Y, and&#xD;
             K219Q/E/N/R),T69-insertions, or K65R/E/N in RT&#xD;
&#xD;
          -  No desire to switch from current ARVs&#xD;
&#xD;
          -  An opportunistic illness indicative of stage 3 HIV diagnosed within the 30 days prior&#xD;
             to screening&#xD;
&#xD;
          -  Participants experiencing decompensated cirrhosis (e.g., ascites, encephalopathy, or&#xD;
             variceal bleeding)&#xD;
&#xD;
          -  Have been treated with immunosuppressant therapies or chemotherapeutic agents within 3&#xD;
             months of study screening, or expected to receive these agents or systemic steroids&#xD;
             during the study (eg, corticosteroids, immunoglobulins, and other immune- or&#xD;
             cytokine-based therapies)&#xD;
&#xD;
          -  Malignancy within 5 years of screening other than cutaneous Kaposi's sarcoma,&#xD;
             completely resected non -melanoma skin cancer (basal cell carcinoma or non-invasive&#xD;
             cutaneous squamous carcinoma), or completely resected carcinoma in-situ of the cervix&#xD;
             (CIN 3) or anus (AIN 3). A prior malignancy treated with curative therapy and for&#xD;
             which there has been no evidence of disease for at least five years prior to screening&#xD;
             is allowed&#xD;
&#xD;
          -  Current alcohol or substance use judged by the Investigator to potentially interfere&#xD;
             with participant study compliance&#xD;
&#xD;
          -  Active, serious infections (other than HIV-1 infection) requiring antibiotic or&#xD;
             antifungal therapy within 30 days prior to Day 1&#xD;
&#xD;
          -  Participation in any other clinical trial, including observational studies, without&#xD;
             prior approval from the sponsor is prohibited while participating in this trial&#xD;
&#xD;
          -  Any other clinical condition or prior therapy that, in the opinion of the&#xD;
             Investigator, would make the participant unsuitable for the study or unable to comply&#xD;
             with the dosing requirements&#xD;
&#xD;
          -  Known hypersensitivity to FDC of B/F/TAF tablets, their metabolites, or formulation&#xD;
             excipient&#xD;
&#xD;
          -  Females who are pregnant (as confirmed by positive serum pregnancy test)&#xD;
&#xD;
          -  Females who are breastfeeding&#xD;
&#xD;
          -  Acute hepatitis in the 30 days prior to randomization&#xD;
&#xD;
          -  Active tuberculosis infection.&#xD;
&#xD;
        Note: Other protocol defined Inclusion/Exclusion criteria may apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gilead Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Gilead Sciences</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alabama Medical Group, PC</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente Los Angeles Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90027</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruane Clinical Research Group Inc.</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mills Clinical Research</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highland Hospital- Alameda Health System</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>One Community Health</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95811</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95825</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kaiser Permanente, Department of Infectious Diseases</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Whitman-Walker Health</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20005</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Hospital</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dupont Circle Physician's Group</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Health Institute</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20017</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capital Medical Associates, PC</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20036</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The GW Medical Faculty Associates</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midland Florida Clinical Research Center, LLC</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therafirst Medical Center</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gary J. Richmond, M.D., P.A.</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midway Immunology and Research Center</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Healthcare Foundation - South Beach</name>
      <address>
        <city>Miami Beach</city>
        <state>Florida</state>
        <zip>33140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHF- The Kinder Medical Group</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine Division of Infectious Disease</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Orlando Immunology Center</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32803-1851</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Hospital Comprehensive Research Institute</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Research &amp; Treatment Center of the Treasure Coast</name>
      <address>
        <city>Vero Beach</city>
        <state>Florida</state>
        <zip>32960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Triple O Research Institute, P.A.</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory Hospital Midtown Infectious Disease Clinic</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta ID Group, PC</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University Medical Center</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Infectious Disease Specialist of Atlanta</name>
      <address>
        <city>Decatur</city>
        <state>Georgia</state>
        <zip>30033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercer University, Department of Internal Medicine</name>
      <address>
        <city>Macon</city>
        <state>Georgia</state>
        <zip>31201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chatham County Health Department</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>31401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Howard Brown Health Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NorthStar Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60657</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana CTSI Clinical Research Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46077</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Medical Center- New Orleans (UMCNO)</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SLVHCS Building J, 7th floor, Outpatient Infectious Disease Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CrescentCare Health</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham and Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Claudia T. Martorell, MD, LLC d/b/a The Research Institute</name>
      <address>
        <city>Springfield</city>
        <state>Massachusetts</state>
        <zip>01105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Be Well Medical Center</name>
      <address>
        <city>Berkley</city>
        <state>Michigan</state>
        <zip>48072</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University- Integrative Bioscience Center</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John Newland Medical Associates</name>
      <address>
        <city>Southfield</city>
        <state>Michigan</state>
        <zip>48075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center, Positive Care Clinic</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>G.V. 'Sonny' Montgomery VAMC</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton Clinical Research</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical: Saint Louis University, New Hope Clinic</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southampton Healthcare, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63139</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntridge Family Clinic</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Prime Healthcare Services- St. Michael's LLC d/b/a Saint Michael's Medical Center</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jacobi Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10467</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Shore University Hospital/Division of Infectious Diseases</name>
      <address>
        <city>Manhasset</city>
        <state>New York</state>
        <zip>11030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NC TraCS Institute-CTRC; University of North Carolina at Chapel Hill</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Physicians</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Health System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Carolina University, The Brody School of Medicine, ECU Adult Specialty Care</name>
      <address>
        <city>Greenville</city>
        <state>North Carolina</state>
        <zip>27834</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rosedale Infectious Diseases</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AHF</name>
      <address>
        <city>Pensacola</city>
        <state>North Carolina</state>
        <zip>32504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Forest University Health Sciences</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati College of Medicine</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MetroHealth Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Perelman Center for Advanced Medicine at the Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19066</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Philadelphia FIGHT Community Health Centers</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Health Richland</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Hope Foundation</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AIDS Arms, Inc. DBA Prism Health North Texas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Texas Infectious Diseases Consultants, P.A.</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tarrant County Infectious Disease Associates</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts, PA</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Street Health Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Access Network</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Crofoot Research Center, INC (dba Gordon E. Crofoot MD PA)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DCOL Center for Clinical Research</name>
      <address>
        <city>Longview</city>
        <state>Texas</state>
        <zip>75605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Community Health Care, Hilltop Medical Clinic</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Andreatta K, D'Antoni ML, Chang S, Parvangada A, Martin R, Blair C, et al. Preexisting Resistance and Week 48 Virologic Outcomes after Switching to B/F/TAF in African American Adults With HIV [Presentation]. IDWeek Virtual; 2020b 21-25 October.</citation>
  </results_reference>
  <results_reference>
    <citation>Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopol M, McDonald C, Blair C, Andreatta K, Collins SE, Brainard D, Martin H. Week-48 Outcomes From the BRAAVE 2020 Study: a Randomized Switch to B/F/TAF in African-American Adults With HIV, IDWeek 2020, October 21-25. Abstract 1046.</citation>
  </results_reference>
  <results_reference>
    <citation>Andreatta K, D'Antoni ML, Chang S, Martin R, Blair C, Collins SE, et al. Preexisting Resistance and B/F/TAF Switch Efficacy in African Americans [Poster 509]. Conference on Retroviruses and Opportunistic Infections (CROI); 2020b 08-11 March; Boston, MA.</citation>
  </results_reference>
  <results_reference>
    <citation>Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopol M, McDonald C, Blair C, Andreatta K, Collins SE, Brainard D, Martin H. Randomized Switch to B/F/TAF in African American Adults with HIV. Conference on Retroviruses and Opportunistic Infections 2020, March 7-11, Boston MA. Abstract 2979.</citation>
  </results_reference>
  <results_reference>
    <citation>Hagins D, Kumar P, Saag M, Wurapa AK, Brar I, Berger D, Osiyemi O, Hileman CO, Ramgopal MN, McDonald C, Blair C, Andreatta K, Collins SE, Brainard DM, Martin H; BRAAVE2020 Investigators. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study. J Acquir Immune Defic Syndr. 2021 Sep 1;88(1):86-95. doi: 10.1097/QAI.0000000000002731.</citation>
    <PMID>34397746</PMID>
  </results_reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 13, 2018</study_first_submitted>
  <study_first_submitted_qc>August 13, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2018</study_first_posted>
  <results_first_submitted>August 12, 2020</results_first_submitted>
  <results_first_submitted_qc>August 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 27, 2020</results_first_posted>
  <last_update_submitted>August 9, 2021</last_update_submitted>
  <last_update_submitted_qc>August 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified external researchers may request IPD for this study after study completion. For more information, please visit our website at https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_time_frame>18 months after study completion</ipd_time_frame>
    <ipd_access_criteria>A secured external environment with username, password, and RSA code.</ipd_access_criteria>
    <ipd_url>https://www.gilead.com/science-and-medicine/research/clinical-trials-transparency-and-data-sharing-policy</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>June 27, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03631732/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Week 24 Analysis</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 30, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03631732/SAP_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Final Analysis</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 16, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03631732/SAP_002.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan: Week 48 Analysis</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>March 3, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/32/NCT03631732/SAP_003.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Participants were enrolled at study centers in the United States. The first participant was screened on 28 August 2018. The last study visit occurred on 19 August 2020.</recruitment_details>
      <pre_assignment_details>The following NRTIs &amp; 3rd agents were allowed:&#xD;
NRTIs:abacavir, emtricitabine, lamivudine, tenofovir alafenamide, tenofovir disoproxil fumarate, zidovudine;&#xD;
3rd agents:delavirdine,efavirenz, nevirapine, rilpivirine,dolutegravir, elvitegravir,raltegravir, doravirine, atazanavir, darunavir, lopinavir, nelfinavir, saquinavir, tipranavir, maraviroc</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>B/F/TAF</title>
          <description>Participants received bictegravir /emtricitabine/tenofovir alafenamide (B/F/TAF) (50/200/25 mg) fixed dose combination (FDC) tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
        <group group_id="P2">
          <title>Stay on Baseline Regimen (SBR)/ Delayed B/F/TAF</title>
          <description>Participants stayed on baseline regimen consisting of 2 nucleos(t)Ide reverse transcriptase inhibitors (NRTIs) and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Phase Up to Week 24</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="331"/>
                <participants group_id="P2" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="324"/>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized but not treated</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>B/F/TAF Treatment Phase (After Week 24)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="319">5 participants completed 24 weeks of the study, but did not receive study treatment after Week 24.</participants>
                <participants group_id="P2" count="163"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="303"/>
                <participants group_id="P2" count="158"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrew Consent</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator's discretion</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).</population>
      <group_list>
        <group group_id="B1">
          <title>B/F/TAF</title>
          <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
        <group group_id="B2">
          <title>Stay on Baseline Regimen/ Delayed B/F/TAF</title>
          <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks with a delayed switch to B/F/TAF (50/200/25 mg) FDC tablet administered orally, once daily until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="330"/>
            <count group_id="B2" value="165"/>
            <count group_id="B3" value="495"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47" spread="12.3"/>
                    <measurement group_id="B2" value="48" spread="12.2"/>
                    <measurement group_id="B3" value="47" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="101"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="156"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="229"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="339"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="315"/>
                    <measurement group_id="B2" value="160"/>
                    <measurement group_id="B3" value="475"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="285"/>
                    <measurement group_id="B2" value="154"/>
                    <measurement group_id="B3" value="439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HIV-1 RNA Category</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt; 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="325"/>
                    <measurement group_id="B2" value="163"/>
                    <measurement group_id="B3" value="488"/>
                  </measurement_list>
                </category>
                <category>
                  <title>≥ 50 copies/mL</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>CD4+ Cell Count</title>
          <units>cells/µL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="765" spread="313.4"/>
                    <measurement group_id="B2" value="757" spread="323.0"/>
                    <measurement group_id="B3" value="763" spread="316.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
        <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants in the Full Analysis Set [included all participants who were randomized into the study, and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1), and did not have pre-existing integrase strand transfer inhibitor resistance-associated mutations (based on historical data)] in B/F/TAF and SBR groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
          <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Full Analysis Set [included all participants who were randomized into the study, and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1), and did not have pre-existing integrase strand transfer inhibitor resistance-associated mutations (based on historical data)] in B/F/TAF and SBR groups were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" lower_limit="0.1" upper_limit="2.2"/>
                    <measurement group_id="O2" value="1.8" lower_limit="0.4" upper_limit="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>B/F/TAF is non-inferior to SBR if the upper bound of the 2-sided 95% confidence interval (CI) of the difference between treatment groups [B/F/TAF - SBR] in the percentage of participants with HIV-1 RNA ≥ 50 copies/mL is less than 6% (i.e., a margin of 6% is applied to non-inferiority assessment).</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>-1.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.8</ci_lower_limit>
            <ci_upper_limit>0.9</ci_upper_limit>
            <estimate_desc>Differences in percentages of participants with HIV-1 RNA &gt;= 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3399</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
        <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Delayed B/F/TAF</title>
            <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had HIV-1 RNA ≥ 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
          <description>The percentage of participants who had HIV-1 RNA ≥ 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
          <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="0.2" upper_limit="2.6"/>
                    <measurement group_id="O2" value="0" lower_limit="0.0" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
        <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants in the Full Analysis Set in the B/F/TAF and SBR groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
          <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Full Analysis Set in the B/F/TAF and SBR groups were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="165"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96.3" lower_limit="93.7" upper_limit="98.1"/>
                    <measurement group_id="O2" value="94.5" lower_limit="89.9" upper_limit="97.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>B/F/TAF is non-inferior to SBR if the lower bound of the 2-sided 95% CI of the difference between treatment groups [B/F/TAF - SBR] in the percentage of participants with HIV-1 RNA &lt; 50 copies/mL is greater than -10% (i.e., a margin of 10% is applied to non-inferiority assessment).</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>1.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>6.8</ci_upper_limit>
            <estimate_desc>Differences in percentages of participants with HIV-1 RNA &lt; 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3532</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set</title>
        <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
        <time_frame>Week 24</time_frame>
        <population>Participants in the Week 24 Per Protocol Analysis Set [included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1), and had not committed any major protocol violation, including the violation of key entry criteria] in the B/F/TAF and SBR groups were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 24 as Defined by the US FDA-Defined Snapshot Algorithm: Week 24 Per Protocol Analysis Set</title>
          <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 24 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status.</description>
          <population>Participants in the Week 24 Per Protocol Analysis Set [included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1), and had not committed any major protocol violation, including the violation of key entry criteria] in the B/F/TAF and SBR groups were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="306"/>
                <count group_id="O2" value="148"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.3" lower_limit="97.7" upper_limit="99.9"/>
                    <measurement group_id="O2" value="98.0" lower_limit="94.2" upper_limit="99.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority</non_inferiority_type>
            <non_inferiority_desc>B/F/TAF is non-inferior to SBR if the lower bound of the 2-sided 95% CI of the difference between treatment groups [B/F/TAF - SBR] in the percentage of participants with HIV-1 RNA &lt; 50 copies/mL is greater than -10% (i.e., a margin of 10% is applied to non-inferiority assessment).</non_inferiority_desc>
            <param_type>Difference in percentages</param_type>
            <param_value>1.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.0</ci_lower_limit>
            <ci_upper_limit>5.3</ci_upper_limit>
            <estimate_desc>Differences in percentages of participants with HIV-1 RNA &lt; 50 copies/mL between treatment groups and 95% CI were calculated based on exact method.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.3356</p_value>
            <method>Fisher Exact</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
        <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
        <time_frame>Week 48</time_frame>
        <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Delayed B/F/TAF</title>
            <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Who Had HIV-1 RNA &lt; 50 Copies/mL at Week 48 as Defined by the US FDA-Defined Snapshot Algorithm: Full Analysis Set</title>
          <description>The percentage of participants who had HIV-1 RNA &lt; 50 copies/mL at Week 48 was analyzed using the snapshot algorithm, which defined a participant's virologic response status using only the viral load at the predefined time point within an allowed window of time, along with study drug discontinuation status. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
          <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="328"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="94.5" lower_limit="91.5" upper_limit="96.7"/>
                    <measurement group_id="O2" value="96.9" lower_limit="93.0" upper_limit="99.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set</title>
        <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Participants in the Full Analysis Set in the B/F/TAF and SBR groups with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 24: Full Analysis Set</title>
          <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
          <population>Participants in the Full Analysis Set in the B/F/TAF and SBR groups with available data were analyzed.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="319"/>
                <count group_id="O2" value="156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="209.3"/>
                    <measurement group_id="O2" value="1" spread="171.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5618</p_value>
            <method>ANOVA</method>
            <method_desc>P-value was calculated from ANOVA model with treatment as a fixed effect.</method_desc>
            <param_type>Difference in LSM</param_type>
            <param_value>11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-27</ci_lower_limit>
            <ci_upper_limit>49</ci_upper_limit>
            <estimate_desc>Difference in LSM (Least square mean) and its 95% C.I. was calculated from ANOVA model with treatment as a fixed effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set</title>
        <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Participants in the Week 24 Per Protocol Analysis Set in the B/F/TAF and SBR groups with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food.</description>
          </group>
          <group group_id="O2">
            <title>Stay on Baseline Regimen (SBR)</title>
            <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 24: Week 24 Per Protocol Analysis Set</title>
          <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment.</description>
          <population>Participants in the Week 24 Per Protocol Analysis Set in the B/F/TAF and SBR groups with available data were analyzed.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="305"/>
                <count group_id="O2" value="144"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13" spread="210.1"/>
                    <measurement group_id="O2" value="4" spread="171.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6632</p_value>
            <method>ANOVA</method>
            <method_desc>P-value was calculated from ANOVA model with treatment as a fixed effect.</method_desc>
            <param_type>Difference in LSM</param_type>
            <param_value>9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-31</ci_lower_limit>
            <ci_upper_limit>48</ci_upper_limit>
            <estimate_desc>Difference in LSM and its 95% C.I. was calculated from ANOVA model with treatment as a fixed effect.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set</title>
        <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
        <time_frame>Baseline to Week 48</time_frame>
        <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Delayed B/F/TAF</title>
            <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CD4+ Cell Count at Week 48: Full Analysis Set</title>
          <description>The analysis includes values up to 1 day after permanent discontinuation of study treatment. By Week 48, participants in B/F/TAF had received 48 weeks of treatment with B/F/TAF, while those in the Delayed B/F/TAF group had received only 24 weeks of treatment with B/F/TAF.</description>
          <population>Participants in the Full Analysis Set in the B/F/TAF and the Delayed B/F/TAF groups with available data were analyzed.</population>
          <units>cells/uL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="309"/>
                <count group_id="O2" value="159"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7" spread="188.6"/>
                    <measurement group_id="O2" value="-8" spread="159.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</title>
        <description>An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.</description>
        <time_frame>First B/F/TAF dose date up to Week 72 plus 30 days</time_frame>
        <population>The B/F/TAF (BVY) Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of BVY study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Delayed B/F/TAF</title>
            <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Adverse Events</title>
          <description>An adverse event (AE) was any untoward medical occurrence in a clinical study participant administered a medicinal product, which did not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and/or unintended sign, symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. A treatment-emergent adverse event was defined as any adverse event with onset date on or after the study treatment start date and no later than 30 days after the study drug stop date; or any adverse event leading to study drug discontinuation.</description>
          <population>The B/F/TAF (BVY) Safety Analysis Set included all participants who were randomized into the study and received at least 1 dose of BVY study drug.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="330"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.3"/>
                    <measurement group_id="O2" value="69.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities</title>
        <description>Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.</description>
        <time_frame>First B/F/TAF dose date up to Week 72 plus 30 days</time_frame>
        <population>Participants in the BVY Safety Analysis Set with available data were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>B/F/TAF</title>
            <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 48 weeks, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
          <group group_id="O2">
            <title>Delayed B/F/TAF</title>
            <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Experiencing Treatment-Emergent Graded Laboratory Abnormalities</title>
          <description>Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The most severe graded abnormality from all tests was counted for each participant. Severity grades were defined by 'Gilead Grading Scale for Severity of AEs and Laboratory Abnormalities'.</description>
          <population>Participants in the BVY Safety Analysis Set with available data were analyzed.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="329"/>
                <count group_id="O2" value="163"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.8"/>
                    <measurement group_id="O2" value="80.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events: First B/F/TAF dose date up to Week 72 plus 30 days. All-Cause Mortality: Randomization up to Week 72 plus 30 days.</time_frame>
      <desc>The Safety Analysis Set included all participants who were randomized into the study and had received at least 1 dose of study treatment (either B/F/TAF or baseline regimen on Day 1).&#xD;
All-Cause Mortality: The All Randomized Analysis Set included all participants who were randomized into the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>B/F/TAF up to Week 24</title>
          <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily for 24 weeks, without regard to food.</description>
        </group>
        <group group_id="E2">
          <title>SBR up to Week 24</title>
          <description>Participants stayed on baseline regimen consisting of 2 NRTIs and a third agent (each taken as prescribed) for 24 weeks administered orally once daily.</description>
        </group>
        <group group_id="E3">
          <title>B/F/TAF After Week 24</title>
          <description>Participants received B/F/TAF (50/200/25 mg) FDC tablet orally once daily from Week 24 to Week 48, without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
        <group group_id="E4">
          <title>Delayed B/F/TAF</title>
          <description>Participants in SBR group who switched to B/F/TAF group at Week 24 received B/F/TAF (50/200/25 mg) FDC tablet orally, once daily from Week 24 until Week 48 without regard to food. At Week 48, participants who wished to continue on B/F/TAF were given the option to receive B/F/TAF FDC for up to an additional 24 weeks or until they had access to B/F/TAF, whichever occurred first.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="331"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="20" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Gastric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Burn infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Covid-19</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Diarrhoea infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hyperglycaemic hyperosmolar nonketotic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lung adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Vertebral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Bipolar I disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Homicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypovolaemic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 23.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="53" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="26" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="163"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="330"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="165"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="319"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="163"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>After conclusion of the study and without prior written approval from Gilead, investigators in this study may communicate, orally present, or publish in scientific journals or other media only after the following conditions have been met:&#xD;
The results of the study in their entirety have been publicly disclosed by or with the consent of Gilead in an abstract, manuscript, or presentation form; or&#xD;
The study has been completed at all study sites for at least 2 years</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gilead Clinical Study Information Center</name_or_title>
      <organization>Gilead Sciences</organization>
      <phone>1-833-445-3230 (GILEAD-0)</phone>
      <email>GileadClinicalTrials@gilead.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

